Dr Reddy's signs pact with Citius Pharma to sell rights to anti-cancer agent
Dr Reddy’s signs pact with Citius Pharma to sell rights to anti-cancer agent
Dr Reddy’s Laboratories Ltd. on Saturday announced that it has entered into a definitive agreement with Citius Pharmaceuticals to sell its rights to E7777 (an engineered IL-2-diphtheria toxin fusion protein) and certain related assets. Under the terms of agreement, Dr Reddy’s will receive $40 million upfront upon the closing of the transaction, followed by approval milestone payment of up to…
View On WordPress










